By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

Eli Lily continues to dominate the weight loss market, willing to crush any competitor that threatens its dominance.

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Eli Lilly has partnered with direct-to-consumer health-care startup Ro to offer more affordable single-dose vials of its ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

Losing weight can be a challenge for many. With so many variables present in everyday life, including stress, lack of sleep, ...

The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...

Medication fills for Zepbound have increased by more than 300% since the start of the year. The average out-of-pocket cost for patients was $230 per fill — the highest of any medication included in ...